礼来(LLY.US)胰淀素受体激动剂启动III期临床

Group 1 - The core point of the article is that Eli Lilly (LLY.US) has initiated its first Phase III clinical trial (ENLIGHTEN-2) for Eloralintide (LY3841136) on December 15, focusing on its efficacy and safety in treating obese or overweight patients with type 2 diabetes [1] - The Phase III study aims to evaluate the effectiveness of Eloralintide, administered in four doses via subcutaneous injection, compared to a placebo [1] - The primary endpoint of the study is the percentage change in body weight from baseline at week 64 [1] Group 2 - Eloralintide is an AMYR receptor agonist developed by Eli Lilly, which may reduce caloric intake by influencing appetite or increasing satiety [1]